Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

BBIO

BridgeBio Pharma Inc

Feb 13 • 04:00PM ET

75.25

-0.81 -1.06 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BMRN BLUE CRSP NBIX SRPT ALNY RARE PRTA FOLD

| Held by: VTI VB IWM VBK VXF XBI IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-4.19	Insider Own	14.53%	Shs Outstand	192.63M	Perf Week	10.58%
Market Cap	14.50B	Forward P/E	-	EPS next Y	-1.55	Insider Trans	-3.80%	Shs Float	164.71M	Perf Month	-3.40%
Enterprise Value	16.57B	PEG	-	EPS next Q	-0.71	Inst Own	88.48%	Short Float	12.13%	Perf Quarter	13.64%
Income	-797.12M	P/S	40.99	EPS this Y	-19.48%	Inst Trans	0.97%	Short Ratio	7.80	Perf Half Y	47.03%
Sales	353.78M	P/B	-	EPS next Y	54.88%	ROA	-95.85%	Short Interest	19.98M	Perf YTD	-1.62%
Book/sh	-10.03	P/C	22.45	EPS next 5Y	-	ROE	-	52W High	84.94 -11.41%	Perf Year	138.43%
Cash/sh	3.35	P/FCF	-	EPS past 3/5Y	9.60% -3.04%	ROIC	-105.23%	52W Low	28.33 165.67%	Perf 3Y	549.27%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	47.10% 40.48%	Gross Margin	95.00%	Volatility	6.67% 5.40%	Perf 5Y	11.71%
Dividend TTM	-	EV/Sales	46.84	EPS Y/Y TTM	-73.59%	Oper. Margin	-168.17%	ATR (14)	4.44	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.76	Sales Y/Y TTM	62.46%	Profit Margin	-225.31%	RSI (14)	50.93	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	3.88	EPS Q/Q	-10.81%	SMA20	-0.44%	Beta	1.10	Target Price	97.95
Payout	-	Debt/Eq	-	Sales Q/Q	4318.01%	SMA50	-0.23%	Rel Volume	1.10	Prev Close	76.06
Employees	730	LT Debt/Eq	-	Earnings	Oct 29 AMC	SMA200	34.70%	Avg Volume	2.56M	Price	75.25
IPO	Jun 27, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-6.25% 13.24%	Trades		Volume	2,818,629	Change	-1.06%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Initiated	Barclays	Overweight	$157
Jan-06-26	Initiated	Morgan Stanley	Overweight	$96
Dec-11-25	Initiated	Bernstein	Outperform	$94
Jul-30-25	Resumed	Raymond James	Outperform	$56
Jul-21-25	Initiated	Truist	Buy	$66
Jul-14-25	Initiated	Jefferies	Buy	$70
Jul-09-25	Upgrade	Oppenheimer	Perform → Outperform	$60
Jun-17-25	Initiated	Wolfe Research	Outperform	$49
Mar-31-25	Initiated	Redburn Atlantic	Buy	$50
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-03-24	Initiated	Oppenheimer	Perform
Sep-04-24	Initiated	Piper Sandler	Overweight	$46
Mar-21-24	Resumed	Raymond James	Outperform	$45
Jan-31-24	Initiated	BMO Capital Markets	Market Perform	$37
Dec-08-23	Initiated	Wells Fargo	Overweight	$58
Dec-08-23	Initiated	Wells Fargo	Overweight
Nov-07-23	Initiated	Citigroup	Buy	$42
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Jul-18-23	Downgrade	Jefferies	Buy → Hold	$24 → $33
Apr-19-23	Initiated	Evercore ISI	Outperform	$40

Show Previous Ratings

Today 09:05AM	Tyra Biosciences price target raised to $53 from $37 at Wedbush (TipRanks)
Feb-13-26 04:34PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
Feb-12-26 07:33AM	BridgeBio Unveils Positive Results For Its Most 'Hotly Debated' Phase 3 Drug (Investor's Business Daily)
03:47PM	BridgeBio Pharma shares rise on compelling Phase 3 trial results for achondroplasia drug (Proactive)
12:44PM	BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 (Benzinga)
10:00AM	Loading…
10:00AM	BridgeBio Pharma (BBIO) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
09:16AM	BridgeBio Pharma Touts Strong Phase 3 PROPEL-3 Data for Oral Infigratinib in Achondroplasia (MarketBeat)
07:30AM	BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia (GlobeNewswire)
02:30AM	BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis (BioPharma Dive)
Feb-09-26 02:44PM	Buy the Dip on This Biotech Stock After Recent Fall (Schaeffer's Research) +6.23%
03:26AM	BridgeBio Pharma (BBIO) Surges 6.8%: Is This an Indication of Further Gains? (Zacks)
Feb-06-26 02:20AM	BridgeBio (BBIO) Tumbles 15%, Mirrors Marked Bleed (Insider Monkey) +6.78%
Jan-27-26 05:10PM	CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
04:01PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-23-26 07:40AM	Wells Fargo Remains a Buy on BridgeBio Pharma (BBIO) (Insider Monkey)
04:57AM	Loading…
Jan-20-26 04:57AM	Analysts Remain Positive on BridgeBio Pharma, Inc. (BBIO) After Strong 2025 Results (Insider Monkey)
Jan-16-26 01:00AM	BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 (GlobeNewswire)
Jan-14-26 04:01PM	BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027 (GlobeNewswire)
Jan-13-26 12:02AM	BridgeBio Pharma Highlights Attruby Surge, Preannounces $146M Q4 Revenue at JPM Healthcare Conference (MarketBeat)
Jan-12-26 10:30AM	BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
10:18AM	JPM Preannouncements Take Their Toll As Alnylam Slides, Tempus, Day One Pop (Investor's Business Daily)
Jan-09-26 10:18AM	BridgeBio Pharma Investor Update: PROPEL 3 Last Visit Set as Infigratinib Phase 3 Readout Nears (MarketBeat)
Jan-05-26 07:30AM	BridgeBio to Participate in the J.P. Morgan Healthcare Conference (GlobeNewswire) -6.15%
Jan-02-26 07:30AM	BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET (GlobeNewswire)
Dec-22-25 04:01PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-11-25 09:39AM	PayPal downgraded, Roku upgraded: Wall Street's top analyst calls (The Fly)
09:17AM	Here Are Thursdays Top Wall Street Analyst Research Calls: American Eagle Outfitters, Ferrari, Intuitive Surgical, Roku, PayPal, Synopsis, Visa, and More (24/7 Wall St.)
09:17AM	Crypto Market 2026 Predictions: Which Coins Will 10x and Which Will Crash? (24/7 Wall St.)
Dec-10-25 12:00PM	This Hot Biotech Stock Just Set New All-Time Highs (Barchart)
Dec-02-25 08:02AM	How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint (Investor's Business Daily)
07:30AM	Loading…
Dec-01-25 07:30AM	Should You Grab This Strong Buy Growth Stock With 56% Upside? (Barchart)
Nov-25-25 07:30AM	BridgeBio to Participate in December Investor Conferences (GlobeNewswire)
Nov-24-25 03:29PM	Biotech Stock Could Turn 4-Year Peak Into Records (Schaeffer's Research)
Nov-19-25 04:01PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-08-25 10:41AM	Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations (GlobeNewswire)
Nov-04-25 08:09PM	BridgeBio Pharma Inc (BBIO) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ... (GuruFocus.com)
07:30AM	BridgeBio to Participate in November Investor Conferences (GlobeNewswire)
Nov-03-25 07:30AM	BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025 (GlobeNewswire)
Oct-30-25 07:20PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
04:15PM	Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
09:49AM	Alnylam Stock Has Already Doubled In 2025. But It Took A Hit On Earnings. (Investor's Business Daily)
Oct-29-25 05:15PM	BridgeBio Pharma (BBIO) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:28PM	BridgeBio Pharma Lines Up Another 'Domino' As It Nears A Record High (Investor's Business Daily)
04:14PM	BridgeBio Pharma: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
07:00AM	BridgeBio Reports Positive Phase 3 Topline Results for Encaleret in Patients with Autosomal Dominant Hypocalcemia Type 1 (GlobeNewswire)
03:55AM	BridgeBio chalks up another win for its rare disease research (BioPharma Dive)
Oct-28-25 04:01PM	BridgeBio to Report Phase 3 Results for Encaleret in ADH1 CALIBRATE Study on Wednesday, October 29th (GlobeNewswire)
09:14AM	BridgeBio Pharma (BBIO) Soars 17.1%: Is Further Upside Left in the Stock? (Zacks)
05:26AM	BridgeBio Pharma (BBIO) Soars to All-Time High on Stellar Drug Trial Result (Insider Monkey)
Oct-27-25 01:18PM	BridgeBios stock up as muscular dystrophy therapy meets Phase III endpoints (Clinical Trials Arena) +17.14%
07:00AM	BridgeBio Reports Positive Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study (GlobeNewswire)
04:02AM	BridgeBio to seek approval of limb-girdle drug following new study data (BioPharma Dive)
Oct-24-25 04:01PM	BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week (GlobeNewswire)
Oct-13-25 12:47PM	This Pharma Play, The IBD Stock Of The Day, Is Offering Another Entry Amid 100% Advance This Year (Investor's Business Daily)
Oct-03-25 04:01PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-02-25 04:55PM	UBS Reaffirms Buy on BridgeBio (BBIO) With Optimism Around Attruby Launch (Insider Monkey)
09:46AM	BridgeBio Pharma, Inc. (BBIO) Retains $68 Target on Strong Launch Dynamics (Insider Monkey)
Oct-01-25 06:58PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
11:05AM	Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra? (Zacks)
Sep-29-25 04:24PM	BridgeBio, Up 80% This Year, Just Unveiled Promising News For Its Pfizer Rival (Investor's Business Daily)
10:42AM	BridgeBio's Acoramidis Cuts Risk Within Weeks In Rare Heart Condition (Benzinga)
Sep-28-25 11:20AM	BridgeBio, Up 80% This Year, Just Unveiled Promising News For Its Pfizer Rival (Investor's Business Daily)
11:15AM	Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM (GlobeNewswire)
Sep-24-25 02:12AM	H.C. Wainwright Reiterates a Buy on BridgeBio Pharma (BBIO) (Insider Monkey)
01:58AM	BridgeBio Pharma's Encaleret Shows Positive Phase 2 Results, Normalizes Calcium in Post-Surgical Hypoparathyroidism (Insider Monkey)
Sep-22-25 07:30AM	BridgeBio to Present Additional Cardiovascular Outcomes Data from ATTRibute-CM at the HFSA Annual Scientific Meeting 2025 (GlobeNewswire)
Sep-10-25 04:01PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-08-25 10:15AM	Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth? (Zacks)
Sep-06-25 02:30PM	Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism (GlobeNewswire)
Sep-05-25 07:00PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
Sep-03-25 07:30AM	BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET (GlobeNewswire)
Sep-02-25 07:03PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
07:30AM	BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism (GlobeNewswire)
Aug-30-25 07:15AM	Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension (GlobeNewswire)
Aug-28-25 11:49PM	Here's What Wall Street Thinks About BridgeBio Pharma (BBIO) (Insider Monkey) +6.01%
06:48PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
10:10AM	Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum? (Zacks)
Aug-27-25 07:30AM	BridgeBio to Participate in September Investor Conferences (GlobeNewswire)
Aug-25-25 07:30AM	BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025 (GlobeNewswire)
Aug-20-25 12:34AM	TD Cowen Reiterates Buy Rating on BridgeBio Pharma (BBIO) on Strong Attruby Sales (Insider Monkey)
Aug-12-25 10:56AM	Skeletal Dysplasia Market Growth Analysis 2025-2030 Featuring BioMarin Pharma, BridgeBio Pharma, Ascendis Pharma, Ipsen, QED Therapeutics and Other Major Players (GlobeNewswire)
Aug-06-25 02:18PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research) -8.94%
07:33AM	Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics (GlobeNewswire)
07:30AM	Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share (BioPharma Dive)
03:29AM	BridgeBio Pharma Inc (BBIO) Q2 2025 Earnings Call Highlights: Record Revenue Surge and ... (GuruFocus.com)
Aug-05-25 05:25PM	BridgeBio Pharma (BBIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:26PM	BridgeBio Pharma: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Aug-04-25 09:22AM	BridgeBio Pharma Inc (BBIO) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Jul-31-25 10:00AM	Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-30-25 12:37PM	Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains. (Barrons.com)
09:40AM	Peloton upgraded, Booking downgraded: Wall Street's top analyst calls (The Fly)
Jul-29-25 10:00AM	BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-25-25 11:29PM	Leerink Partners Maintains a Buy on BridgeBio Pharma (BBIO) With a $56 PT (Insider Monkey)
Jul-24-25 11:47PM	Truist Sees Upside in BridgeBio Pharma's (BBIO) ATTR-CM Strategy (Insider Monkey)
Jul-23-25 07:30AM	Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1 (GlobeNewswire)
Jul-22-25 07:30AM	BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET (GlobeNewswire)
Jul-16-25 06:17AM	These 2 Momentum Stocks Got a Bullish Nod Heres Why They Could Reach New Highs (TipRanks)
Jul-14-25 09:32AM	Rivian downgraded, PayPal upgraded: Wall Street's top analyst calls (The Fly)

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kumar Neil	Chief Executive Officer	Feb 10 '26	Sale	71.94	40,000	2,877,580	695,686	Feb 12 04:39 PM
Kumar Neil	Chief Executive Officer	Feb 11 '26	Sale	71.78	40,000	2,871,087	675,686	Feb 12 04:39 PM
Kumar Neil	Chief Executive Officer	Jan 09 '26	Sale	77.11	40,000	3,084,313	715,686	Jan 12 09:01 PM
Kumar Neil	Chief Executive Officer	Jan 08 '26	Sale	73.97	40,000	2,958,855	735,686	Jan 12 09:01 PM
KUMAR HALDEA REVOCABLE TRUST U	Director	Jan 08 '26	Proposed Sale	74.27	120,000	8,912,400		Jan 08 04:23 PM
KUMAR HALDEA FAMILY IRREVOCABL	Director	Jan 08 '26	Proposed Sale	74.27	100,000	7,427,000		Jan 08 04:23 PM
Kumar Neil	Chief Executive Officer	Dec 15 '25	Sale	74.64	30,011	2,239,902	228,776	Dec 16 06:27 PM
NEIL KUMAR	Director	Dec 15 '25	Proposed Sale	75.15	30,011	2,255,327		Dec 15 04:23 PM
Apuli Maricel	Chief Accounting Officer	Dec 08 '25	Sale	74.26	2,000	148,520	130,297	Dec 10 07:53 AM
Kumar Neil	Chief Executive Officer	Dec 04 '25	Sale	74.40	40,000	2,975,913	775,686	Dec 08 05:54 PM
Kumar Neil	Chief Executive Officer	Dec 05 '25	Sale	73.31	40,000	2,932,563	755,686	Dec 08 05:54 PM
Kumar Neil	Chief Executive Officer	Nov 20 '25	Sale	65.84	26,156	1,722,224	228,776	Nov 24 06:46 PM
NEIL KUMAR	Director	Nov 20 '25	Proposed Sale	65.54	26,156	1,714,264		Nov 20 04:20 PM
Lo Andrew	Director	Nov 18 '25	Sale	65.69	55,000	3,613,069	50,583	Nov 19 05:08 PM
Lo Andrew	Director	Nov 17 '25	Sale	66.67	40,599	2,706,593	14,089	Nov 19 05:08 PM
Scott Randal W.	Director	Nov 17 '25	Option Exercise	16.75	10,000	167,500	21,589	Nov 19 05:06 PM
Scott Randal W.	Director	Nov 17 '25	Sale	66.65	10,000	666,465	11,589	Nov 19 05:06 PM
Trimarchi Thomas	President and CFO	Nov 17 '25	Sale	66.46	16,934	1,125,404	382,830	Nov 18 07:28 PM
ANDREW W LO	Director	Nov 18 '25	Proposed Sale	65.69	55,000	3,613,066		Nov 18 04:06 PM
ANDREW W LO	Director	Nov 17 '25	Proposed Sale	66.67	40,599	2,706,589		Nov 17 05:24 PM
RANDAL SCOTT	Director	Nov 17 '25	Proposed Sale	66.39	10,000	663,900		Nov 17 04:27 PM
THOMAS TRIMARCHI	Officer	Nov 17 '25	Proposed Sale	66.46	16,934	1,125,403		Nov 17 04:11 PM
Valantine Hannah	Director	Nov 12 '25	Option Exercise	48.45	25,484	1,234,700	32,949	Nov 14 04:50 PM
Valantine Hannah	Director	Nov 12 '25	Sale	66.07	25,484	1,683,728	7,465	Nov 14 04:50 PM
Hannah A Valantine	Director	Nov 12 '25	Proposed Sale	66.07	25,484	1,683,728		Nov 12 04:04 PM
Kumar Neil	Chief Executive Officer	Nov 06 '25	Sale	63.15	40,000	2,526,117	815,686	Nov 10 05:33 PM
Kumar Neil	Chief Executive Officer	Nov 07 '25	Sale	61.42	40,000	2,456,994	795,686	Nov 10 05:33 PM
DANIELS RONALD J	Director	Nov 06 '25	Option Exercise	34.65	61,031	2,114,724	78,022	Nov 07 06:03 PM
DANIELS RONALD J	Director	Nov 06 '25	Sale	63.72	61,031	3,888,999	16,991	Nov 07 06:03 PM
RONALD J DANIELS	Director	Nov 06 '25	Proposed Sale	63.72	61,031	3,888,999		Nov 06 04:54 PM
MCCORMICK FRANK	Director	Oct 29 '25	Sale	66.58	198,359	13,206,528	679,979	Oct 31 04:38 PM
Frank McCormick	Director	Oct 29 '25	Proposed Sale	66.58	198,359	13,206,532		Oct 29 05:59 PM
MCCORMICK FRANK	Director	Oct 27 '25	Sale	65.00	1,641	106,665	878,338	Oct 29 05:10 PM
Frank McCormick	Director	Oct 27 '25	Proposed Sale	65.00	1,641	106,665		Oct 27 04:06 PM
Kumar Neil	Chief Executive Officer	Oct 09 '25	Sale	54.80	40,000	2,192,092	835,686	Oct 10 05:40 PM
Kumar Neil	Chief Executive Officer	Oct 08 '25	Sale	54.78	40,000	2,191,350	855,686	Oct 10 05:40 PM
KUMAR HALDEA FAMILY IRREVOCABL	Director	Oct 08 '25	Proposed Sale	54.22	120,000	6,506,400		Oct 08 04:18 PM
KUMAR HALDEA REVOCABLE TRUST U	Director	Oct 08 '25	Proposed Sale	54.22	120,000	6,506,400		Oct 08 04:17 PM
MCCORMICK FRANK	Director	Sep 05 '25	Option Exercise	11.92	74,000	882,080	157,275	Sep 08 06:06 PM
MCCORMICK FRANK	Director	Sep 05 '25	Sale	53.16	74,000	3,933,544	83,275	Sep 08 06:06 PM
Kumar Neil	Chief Executive Officer	Sep 05 '25	Sale	53.05	40,000	2,122,047	875,686	Sep 08 06:05 PM
Kumar Neil	Chief Executive Officer	Sep 04 '25	Sale	51.34	40,000	2,053,788	895,686	Sep 08 06:05 PM
FRANK P. MCCORMICK	Director	Sep 05 '25	Proposed Sale	53.14	74,000	3,932,057		Sep 05 04:46 PM
Trimarchi Thomas	President and CFO	Aug 21 '25	Sale	49.48	42,237	2,090,081	421,081	Aug 22 04:58 PM
Kumar Neil	Chief Executive Officer	Aug 20 '25	Sale	48.82	26,156	1,276,927	223,090	Aug 22 04:46 PM
THOMAS TRIMARCHI	Officer	Aug 21 '25	Proposed Sale	49.48	42,237	2,090,077		Aug 21 04:10 PM
NEIL KUMAR	Director	Aug 20 '25	Proposed Sale	48.91	26,156	1,279,290		Aug 20 04:23 PM
Trimarchi Thomas	President and CFO	Aug 18 '25	Sale	50.23	17,353	871,722	463,318	Aug 19 07:40 PM
THOMAS TRIMARCHI	Officer	Aug 18 '25	Proposed Sale	50.23	17,353	871,723		Aug 18 04:03 PM
HOMCY CHARLES J	Director	Aug 08 '25	Sale	46.05	250,000	11,512,443	966,674	Aug 12 07:06 PM
HOMCY CHARLES J	Director	Aug 11 '25	Sale	48.00	50,000	2,400,000	916,674	Aug 12 07:06 PM
Apuli Maricel	Chief Accounting Officer	Aug 07 '25	Sale	45.44	1,000	45,440	141,859	Aug 11 06:29 PM
Kumar Neil	Chief Executive Officer	Aug 08 '25	Sale	46.22	40,000	1,848,828	915,686	Aug 11 06:12 PM
Kumar Neil	Chief Executive Officer	Aug 07 '25	Sale	45.45	40,000	1,818,121	935,686	Aug 11 06:12 PM
CHARLES J HOMCY	Director	Aug 11 '25	Proposed Sale	48.00	50,000	2,400,000		Aug 11 04:17 PM
CHARLES J HOMCY	Director	Aug 08 '25	Proposed Sale	46.05	250,000	11,512,420		Aug 08 05:11 PM
Ellis Andrea	Director	Aug 05 '25	Option Exercise	16.75	17,167	287,547	35,756	Aug 07 04:50 PM
Ellis Andrea	Director	Aug 05 '25	Sale	49.00	17,167	841,183	18,589	Aug 07 04:50 PM
ANDREA ELLIS	Director	Aug 05 '25	Proposed Sale	49.00	17,167	841,183		Aug 05 04:26 PM
Kumar Neil	Chief Executive Officer	Jul 02 '25	Sale	42.73	40,000	1,709,050	955,686	Jul 03 04:30 PM
Kumar Neil	Chief Executive Officer	Jul 01 '25	Sale	42.54	40,000	1,701,400	975,686	Jul 03 04:30 PM
VIKING GLOBAL INVESTORS LP	10% Owner	Jun 27 '25	Sale	44.00	3,500,000	154,000,000	18,555,375	Jul 01 07:48 PM
KUMAR HALDEA REVOCABLETRUST U/	Director	Jul 01 '25	Proposed Sale	43.18	120,000	5,181,600		Jul 01 04:31 PM
KUMAR HALDEA FAMILY IRREVOCABL	Director	Jul 01 '25	Proposed Sale	43.18	120,000	5,181,600		Jul 01 04:31 PM
Valantine Hannah	Director	Jun 26 '25	Sale	44.05	2,418	106,504	7,465	Jun 30 05:51 PM
Valantine Hannah	Director	Jun 26 '25	Sale	44.05	2,289	100,824	398	Jun 30 05:51 PM
MCCORMICK FRANK	Director	Jun 24 '25	Sale	44.23	100,000	4,422,800	879,979	Jun 26 05:08 PM
DENIS VON KAEPPLER IRA ROLLOVE	client's wife is a BoD	Jun 26 '25	Proposed Sale	44.03	1,891	83,261		Jun 26 04:19 PM
HANNAH VALANTINE & DENIS VON K	spouse of bod / bod is joint o	Jun 26 '25	Proposed Sale	44.01	1,542	67,863		Jun 26 04:16 PM
HANNAH A VALANTINE & DENIS VON	Officer	Jun 26 '25	Proposed Sale	44.11	876	38,640		Jun 26 04:14 PM
ERICKA VON KAEPPLER & DENIS VO	account owners are spouse and	Jun 26 '25	Proposed Sale	44.13	398	17,562		Jun 26 04:13 PM
MCCORMICK FRANK	Officer	Jun 24 '25	Proposed Sale	44.23	100,000	4,422,803		Jun 24 05:59 PM
Valantine Hannah	Director	Jun 10 '25	Option Exercise	16.75	4,292	71,891	6,056	Jun 11 05:00 PM
Valantine Hannah	Director	Jun 10 '25	Sale	40.00	4,292	171,680	1,764	Jun 11 05:00 PM
HANNAH A VALANTINE	Director	Jun 10 '25	Proposed Sale	40.00	4,292	171,680		Jun 10 04:01 PM
Kumar Neil	Chief Executive Officer	May 20 '25	Sale	33.40	75,000	2,504,978	4,798,447	May 20 06:06 PM
Kumar Neil	Chief Executive Officer	May 19 '25	Sale	33.33	26,156	871,764	217,404	May 20 06:06 PM
NEIL KUMAR	Director	May 19 '25	Proposed Sale	33.84	26,156	885,119		May 19 04:25 PM
KKR Genetic Disorder L.P.	10% Owner	May 12 '25	Sale	34.20	6,000,000	205,200,000	13,260,971	May 14 05:24 PM
KKR Genetic Disorder L.P.	Affiliate	May 12 '25	Proposed Sale	35.68	6,000,000	214,080,000		May 12 09:46 PM
Apuli Maricel	Chief Accounting Officer	May 02 '25	Sale	38.51	1,026	39,509	147,639	May 06 04:45 PM
Lo Andrew	Director	May 02 '25	Sale	38.50	100,000	3,849,900	105,583	May 06 04:42 PM
Lo Andrew	Director	May 02 '25	Proposed Sale	35.23	100,000	3,523,000		May 02 04:36 PM
Kumar Neil	Chief Executive Officer	Apr 22 '25	Sale	34.11	75,000	2,558,025	4,873,447	Apr 24 04:28 PM
Ellis Andrea	Director	Apr 14 '25	Option Exercise	8.45	10,000	84,500	22,000	Apr 16 05:39 PM
Ellis Andrea	Director	Apr 14 '25	Sale	35.00	10,000	350,000	12,000	Apr 16 05:39 PM
ANDREA ELLIS	Director	Apr 14 '25	Proposed Sale	35.00	10,000	350,000		Apr 14 04:21 PM
Ellis Andrea	Director	Apr 01 '25	Option Exercise	8.45	30,000	253,500	42,000	Apr 03 05:11 PM
Ellis Andrea	Director	Apr 01 '25	Sale	34.05	30,000	1,021,500	12,000	Apr 03 05:11 PM
ANDREA ELLIS	Director	Apr 01 '25	Proposed Sale	34.05	30,000	1,021,500		Apr 02 04:48 PM
Kumar Neil	Chief Executive Officer	Mar 25 '25	Sale	36.87	75,000	2,764,943	4,948,447	Mar 27 04:54 PM
Valantine Hannah	Director	Mar 06 '25	Option Exercise	16.75	12,875	215,656	14,639	Mar 10 04:43 PM
Valantine Hannah	Director	Mar 06 '25	Sale	32.58	12,875	419,500	1,764	Mar 10 04:43 PM
KKR Genetic Disorder L.P.	10% Owner	Mar 05 '25	Sale	32.96	6,000,000	197,760,000	19,260,971	Mar 07 06:09 PM
HANNAH A VALANTINE	Director	Mar 06 '25	Proposed Sale	32.58	12,875	419,500		Mar 06 04:06 PM
KKR Genetic Disorder L.P.	Affiliate	Mar 05 '25	Proposed Sale	34.97	6,000,000	209,820,000		Mar 05 09:09 PM
STEPHENSON BRIAN C	CFO and Treasurer	Feb 25 '25	Option Exercise	17.00	8,500	144,500	110,964	Feb 27 05:36 PM
STEPHENSON BRIAN C	CFO and Treasurer	Feb 25 '25	Sale	33.19	8,500	282,115	102,464	Feb 27 05:36 PM
Kumar Neil	Chief Executive Officer	Feb 25 '25	Sale	33.57	75,000	2,517,971	5,023,447	Feb 27 05:12 PM
KUMAR HALDEA REVOCABLE TRUST U	Director	Feb 25 '25	Proposed Sale	36.25	300,000	10,875,000		Feb 25 04:35 PM

Open in Screener

APG

APi Group Corporation

Feb 13 • 04:00PM ET

44.41

+0.51 1.16 %

Industrials • Engineering & Construction • USA • NYSE

APG APi Group Corporation daily Stock Chart

Peers: J ACM PWR FLR AGX DY FIX PRIM TPC VSEC

| Held by: IJH VTI VB VBR VXF MDY XMMO IJK SPMD IWR

Index	-	P/E	122.24	EPS (ttm)	0.36	Insider Own	13.84%	Shs Outstand	415.91M	Perf Week	-0.09%
Market Cap	19.32B	Forward P/E	26.66	EPS next Y	1.67	Insider Trans	-3.36%	Shs Float	374.91M	Perf Month	5.66%
Enterprise Value	21.82B	PEG	1.79	EPS next Q	0.42	Inst Own	79.56%	Short Float	2.32%	Perf Quarter	15.77%
Income	156.00M	P/S	2.52	EPS this Y	18.89%	Inst Trans	-1.78%	Short Ratio	3.67	Perf Half Y	26.67%
Sales	7.66B	P/B	5.69	EPS next Y	14.22%	ROA	3.21%	Short Interest	8.71M	Perf YTD	16.07%
Book/sh	7.80	P/C	34.82	EPS next 5Y	14.87%	ROE	8.71%	52W High	46.11 -3.69%	Perf Year	77.78%
Cash/sh	1.28	P/FCF	33.78	EPS past 3/5Y	-7.92% -16.79%	ROIC	2.50%	52W Low	20.50 116.60%	Perf 3Y	206.14%
Dividend Est.	-	EV/EBITDA	25.61	Sales past 3/5Y	21.22% 11.39%	Gross Margin	28.15%	Volatility	2.97% 2.87%	Perf 5Y	252.65%
Dividend TTM	-	EV/Sales	2.85	EPS Y/Y TTM	129.27%	Oper. Margin	6.91%	ATR (14)	1.27	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.41	Sales Y/Y TTM	10.69%	Profit Margin	2.04%	RSI (14)	62.48	Recom	1.45
Dividend Gr. 3/5Y	- -	Current Ratio	1.48	EPS Q/Q	17.34%	SMA20	3.40%	Beta	1.69	Target Price	45.80
Payout	-	Debt/Eq	0.93	Sales Q/Q	14.18%	SMA50	8.09%	Rel Volume	0.82	Prev Close	43.90
Employees	29000	LT Debt/Eq	0.90	Earnings	Feb 25 BMO	SMA200	23.69%	Avg Volume	2.37M	Price	44.41
IPO	Oct 05, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.64% 3.87%	Trades		Volume	1,952,522	Change	1.16%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-15-25	Upgrade	JP Morgan	Neutral → Overweight	$42
Jun-24-25	Resumed	JP Morgan	Neutral	$46
Jan-22-25	Initiated	Truist	Buy	$45
Jan-14-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$45
Dec-05-24	Initiated	William Blair	Outperform
Mar-15-24	Initiated	Jefferies	Buy	$48
Jan-25-24	Resumed	UBS	Buy	$40
May-17-23	Upgrade	Robert W. Baird	Neutral → Outperform	$27 → $29
Jul-11-22	Upgrade	BofA Securities	Neutral → Buy	$23
Jun-17-22	Initiated	JP Morgan	Neutral	$17
Mar-25-22	Initiated	RBC Capital Mkts	Sector Perform	$24
Mar-22-22	Initiated	BofA Securities	Neutral	$23
Jan-10-22	Downgrade	Robert W. Baird	Outperform → Neutral	$26
Dec-21-21	Resumed	Citigroup	Buy	$28
Sep-22-20	Initiated	Barclays	Overweight	$19
Jun-24-20	Initiated	Robert W. Baird	Outperform	$16
May-27-20	Initiated	UBS	Buy	$13

Show Previous Ratings

Feb-12-26 05:55PM	Bright Horizons Family Solutions (BFAM) Beats Q4 Earnings and Revenue Estimates (Zacks)
Feb-09-26 11:02PM	3 Reasons APG is Risky and 1 Stock to Buy Instead (StockStory)
Feb-08-26 08:31AM	Trump Ally Mullin Buys 10 Stocks, Including These $5 Billion Companies You've Probably Never Heard Of (Benzinga)
Feb-06-26 12:45PM	3 Reasons Why APi (APG) Is a Great Growth Stock (Zacks)
Feb-05-26 07:31PM	Trump Ally Mullin Buys 10 Stocks, Including These $5 Billion Companies You've Probably Never Heard Of (Benzinga)
09:09AM	Loading…
Feb-04-26 09:09AM	Truist Names APi Group (APG) Top Pick as Facility Services Demand Holds Firm (Insider Monkey)
07:30AM	APi Group Confirms Date of Fourth Quarter 2025 Earnings Release and Announces Participation in Upcoming Investor Conferences (Business Wire)
Feb-03-26 07:30AM	APi Group Completes Acquisition of CertaSite (Business Wire)
Feb-02-26 09:40AM	Is Adecco (AHEXY) Stock Outpacing Its Business Services Peers This Year? (Zacks)
Jan-30-26 09:15AM	APi Group Corporation (APG) Hit a 52 Week High, Can the Run Continue? (Zacks)
Jan-29-26 08:15AM	Marsh (MRSH) Q4 Earnings and Revenues Beat Estimates (Zacks)
07:53AM	What Makes APi Group (APG) an Economically Resilient Business Model? (Insider Monkey)
Jan-28-26 01:51AM	APi Group Corporation (APG) Stock Holds Firm Amid Industrial Volatility (Insider Monkey)
Jan-22-26 12:52PM	GPN's Worldpay Expands Its Solutions Reach via Regions Bank Partnership (Zacks)
Jan-21-26 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook APi (APG) (Zacks)
11:58AM	Loading…
11:58AM	Innodata Expands Federal Defense Footprint With SHIELD Award (Zacks)
03:40AM	Zacks Investment Ideas feature highlights: Micron, MicroStrategy and APi Group (Zacks)
Jan-20-26 03:49PM	Insiders Are Buying Thousands of These Shares (Zacks)
12:31PM	3 Business Services Stocks to Watch in a Prospering Industry (Zacks)
Jan-16-26 09:40AM	Are Business Services Stocks Lagging APi Group (APG) This Year? (Zacks)
Jan-13-26 11:33PM	3 Stocks Under $50 with Warning Signs (StockStory)
08:56AM	Willdan Surges 27.7% in Three Months: How to Play the Stock Now? (Zacks)
Jan-12-26 09:50AM	McDonalds Upgraded, Netflix Downgraded: Updated Rankings on Top Blue-Chip Stocks (InvestorPlace)
Jan-11-26 11:39PM	1 Cash-Producing Stock to Target This Week and 2 We Question (StockStory)
Jan-08-26 12:55PM	Euronet Fortifies Presence in Greece With CrediaBank Deal (Zacks)
08:32AM	Can Solid Utility Programs and Planning Work Drive Willdan in 2026? (Zacks)
Jan-07-26 12:42PM	Acuity Brands to Post Q1 Earnings: Here's What You Must Know (Zacks)
Jan-06-26 09:15AM	APi Group Corporation (APG) Hits Fresh High: Is There Still Room to Run? (Zacks)
Jan-05-26 12:45PM	Is APi (APG) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
Dec-31-25 09:40AM	Is APi Group (APG) Stock Outpacing Its Business Services Peers This Year? (Zacks)
09:42AM	Loading…
Dec-15-25 09:42AM	Ford Upgraded, Amazon Downgraded: Updated Rankings on Top Blue-Chip Stocks (InvestorPlace)
Dec-10-25 01:06PM	APi (APG) Stock Is Up, What You Need To Know (StockStory) +5.92%
07:30AM	APi Group Announces Acquisition of CertaSite and Provides Full-Year 2025 Update (Business Wire)
Dec-04-25 12:47PM	APi Group Corporation (APG): A Bull Case Theory (Insider Monkey)
Nov-25-25 07:30AM	-APi Group Announces Participation in the UBS Global Industrials and Transportation Conference- (Business Wire)
Nov-23-25 10:36PM	Construction and Maintenance Services Stocks Q3 In Review: APi (NYSE:APG) Vs Peers (StockStory)
Nov-21-25 09:06AM	3 Industrials Stocks with Questionable Fundamentals (StockStory)
Nov-17-25 11:05AM	Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks (InvestorPlace)
Nov-06-25 12:40AM	The Top 5 Analyst Questions From APi's Q3 Earnings Call (StockStory)
Oct-31-25 02:11PM	APi (APG) Stock Trades Up, Here Is Why (StockStory)
10:25AM	APG Q3 Deep Dive: Inspection Services, M&A, and Project Mix Drive Revenue Growth (StockStory)
Oct-30-25 04:29PM	APi Group Corp (APG) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
10:00AM	APi (APG) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:50AM	APi (APG) Beats Q3 Earnings and Revenue Estimates (Zacks)
08:28AM	APi (NYSE:APG) Delivers Impressive Q3 (StockStory)
07:47AM	APi: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	APi Group Reports Record Third Quarter 2025 Financial Results and Raises Full-Year 2025 Outlook (Business Wire)
Oct-29-25 09:23AM	What To Expect From APi Group Corp (APG) Q3 2025 Earnings (GuruFocus.com)
Oct-28-25 11:18PM	Earnings To Watch: APi (APG) Reports Q3 Results Tomorrow (StockStory)
Oct-23-25 10:00AM	APi (APG) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-22-25 12:02AM	3 Reasons to Sell APG and 1 Stock to Buy Instead (StockStory)
Oct-16-25 07:30AM	APi Group Confirms Date of Third Quarter 2025 Earnings Release (Business Wire)
Oct-10-25 01:50PM	APi Group Recommends Shareholders Reject "Mini-Tender" Offer (Business Wire)
08:13AM	Here's What Supports APi Group's (APG) Attractive Long-Term Upside (Insider Monkey)
Oct-07-25 03:37PM	Is the Options Market Predicting a Spike in APi Group Stock? (Zacks)
Sep-29-25 11:45AM	Acuity Brands Gears Up for Q4 Earnings: Things to Keep in Mind (Zacks)
Sep-15-25 11:35PM	Construction and Maintenance Services Stocks Q2 In Review: APi (NYSE:APG) Vs Peers (StockStory)
Sep-10-25 12:56PM	WU and dLocal Drive Digital Remittance Expansion in Latin America (Zacks)
Sep-01-25 09:40AM	Are Business Services Stocks Lagging APi Group (APG) This Year? (Zacks)
Aug-28-25 12:38AM	3 Profitable Stocks with Open Questions (StockStory)
Aug-22-25 12:32PM	Jacobs Secures Landmark Project to Upgrade New York Roads & Bridges (Zacks)
Aug-21-25 05:40AM	3 Industrials Stocks We Keep Off Our Radar (StockStory)
Aug-20-25 07:30AM	APi Group Announces Upcoming Participation in Jefferies Industrial Conference (Business Wire)
Aug-19-25 08:52AM	Are Options Traders Betting on a Big Move in APi Stock? (Zacks)
Aug-18-25 12:45PM	APi (APG) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
Aug-15-25 09:40AM	Is APi Group (APG) Stock Outpacing Its Business Services Peers This Year? (Zacks)
Aug-14-25 05:52AM	3 Mid-Cap Stocks That Concern Us (StockStory)
Aug-13-25 12:46PM	Jacobs Secures Program Role in Pediatric Megaproject, Stock Up (Zacks)
12:00PM	All You Need to Know About APi (APG) Rating Upgrade to Strong Buy (Zacks)
10:00AM	Best Momentum Stocks to Buy for August 13th (Zacks)
07:47AM	Is it Now A Great Time to Invest in APi Group (APG)? (Insider Monkey)
Aug-12-25 11:14PM	APG Q2 Deep Dive: Organic Growth, M&A Momentum, and Strong Backlog Fuel Outlook (StockStory)
11:09PM	APi's Q2 Earnings Call: Our Top 5 Analyst Questions (StockStory)
Aug-08-25 10:00AM	Best Momentum Stock to Buy for August 8th (Zacks)
Aug-06-25 12:58PM	Global Payments Q2 Earnings Beat on Issuer Solutions Strength (Zacks)
Aug-04-25 07:52AM	APi Group (APG) Investment: A Success in Safety and Growth (Insider Monkey)
Aug-01-25 12:45PM	3 Reasons Growth Investors Will Love APi (APG) (Zacks)
09:27AM	Zacks Industry Outlook Highlights APi, Aramark and Mitie (Zacks)
03:18AM	APi Group Corp (APG) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised ... (GuruFocus.com)
Jul-31-25 01:23PM	3 Business Services Stocks to Watch in a Prospering Industry (Zacks)
09:57AM	APi (NYSE:APG) Surprises With Strong Q2, Stock Soars (StockStory)
09:30AM	APi (APG) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
08:45AM	APi (APG) Beats Q2 Earnings and Revenue Estimates (Zacks)
07:41AM	APi: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	APi Group Reports Second Quarter 2025 Financial Results and Raises Full-Year 2025 Outlook (Business Wire)
Jul-30-25 11:26AM	Visa Q3 Earnings Beat Estimates on Strong Cross-Border Volumes (Zacks)
11:02AM	Western Union Down 4% on Q2 Earnings Miss & Lowered Outlook (Zacks)
10:34AM	Kyndryl Set to Report Q1 Earnings: What's in the Offing? (Zacks)
09:40AM	Is APi Group (APG) Outperforming Other Business Services Stocks This Year? (Zacks)
09:23AM	APi Group Corp (APG) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Jul-29-25 11:08PM	APi Earnings: What To Look For From APG (StockStory)
12:43PM	Aurora Gears Up to Report Q2 Earnings: Here's What to Expect (Zacks)
10:22AM	Aptiv Gears Up to Report Q2 Earnings: Here's What to Expect (Zacks)
Jul-28-25 11:01AM	FIX Delivers Robust EPS Growth: What's Driving the Margin Upside? (Zacks)
09:55AM	S&P Global to Report Q2 Earnings: Here's What You Should Know (Zacks)
Jul-25-25 11:58AM	Verisk Set to Report Q2 Earnings: Here's What You Should Know (Zacks)
11:02AM	TT Gears Up to Report Q2 Earnings: Here's What You Should Know (Zacks)
Jul-24-25 11:45AM	Republic Services to Report Q2 Earnings: What's in the Offing? (Zacks)
10:00AM	APi (APG) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-23-25 11:13AM	ManpowerGroup Stock Improves 5% Since Q2 Earnings Beat (Zacks)

APi Group Corp. engages in the provision of life safety and specialty services. It operates through the Safety Services and Specialty Services segments. The Safety Services segments offers safety services in North America and Europe, focusing on end-to-end integrated occupancy systems (fire protection solutions, HVAC, and entry systems), including design, installation, inspection, and service of these integrated systems. The Specialty Services segment refers to infrastructure services and specialized industrial plant services, which include maintenance and repair of critical infrastructure such as electric, gas, water, sewer, and telecommunications infrastructure. The company was founded by Ashken Ian Guy Handley, Lillie James E and Franklin Martin E in 1926 and is headquartered in New Brighton, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MALKIN ANTHONY E	Director	Dec 10 '25	Buy	39.58	3,000	118,740	7,000	Jan 09 05:11 PM
MALKIN ANTHONY E	Director	Nov 26 '25	Buy	39.46	2,000	78,920	2,000	Jan 09 05:11 PM
MALKIN ANTHONY E	Director	Dec 05 '25	Buy	39.03	2,000	78,060	4,000	Jan 09 05:11 PM
ARSENIADIS JAMES	VP & Chief Accounting Officer	Jan 01 '26	Option Exercise	0.00	1,390	0	12,560	Jan 05 05:33 PM
JACKOLA GLENN DAVID	EVP & Chief Financial Officer	Dec 01 '25	Option Exercise	0.00	6,618	0	19,741	Dec 03 05:10 PM
FRANKLIN MARTIN E	Director	Nov 05 '25	Sale	36.09	340,000	12,271,103	18,968,790	Nov 05 06:24 PM
FRANKLIN MARTIN E	Director	Nov 03 '25	Sale	36.19	300,000	10,857,199	19,568,790	Nov 05 06:24 PM
FRANKLIN MARTIN E	Director	Nov 04 '25	Sale	35.44	260,000	9,214,400	19,308,790	Nov 05 06:24 PM
MEF Holdings, LLLP	Shareholder	Nov 03 '25	Proposed Sale	35.78	900,000	32,202,000		Nov 03 05:04 PM
FRANKLIN MARTIN E	Director	Sep 02 '25	Sale	34.64	1,200,000	41,568,000	19,868,790	Sep 04 05:03 PM
MEF Holdings, LLLP	Shareholder	Sep 02 '25	Proposed Sale	34.64	1,200,000	41,567,615		Sep 02 07:15 PM
LILLIE JAMES E	Director	Aug 11 '25	Sale	34.88	190,000	6,627,200	7,443,101	Aug 13 05:19 PM
LILLIE JAMES E	Director	Aug 12 '25	Sale	35.23	95,000	3,346,850	7,348,101	Aug 13 05:19 PM
LILLIE JAMES E	Director	Aug 11 '25	Sale	34.88	50,000	1,744,000	1,450,019	Aug 13 05:19 PM
LILLIE JAMES E	Director	Aug 12 '25	Sale	35.23	25,000	880,750	1,425,019	Aug 13 05:19 PM
ASHKEN IAN G H	Director	Aug 12 '25	Sale	35.24	205,550	7,243,582	7,968,167	Aug 13 05:19 PM
ASHKEN IAN G H	Director	Aug 11 '25	Sale	35.01	19,450	680,944	8,398,703	Aug 13 05:19 PM
Ian G. H. Ashken	Director	Aug 11 '25	Proposed Sale	34.46	150,000	5,169,000		Aug 11 05:51 PM
James E. Lillie	Director	Aug 11 '25	Proposed Sale	34.46	250,000	8,615,000		Aug 11 05:18 PM
ARSENIADIS JAMES	VP & Chief Accounting Officer	Aug 04 '25	Sale	35.38	4,843	171,345	12,116	Aug 05 05:33 PM
Lambert Louis	SVP, Gen Counsel & Secretary	Aug 02 '25	Option Exercise	0.00	16,769	0	17,770	Aug 05 05:33 PM
ARSENIADIS JAMES	Officer	Aug 04 '25	Proposed Sale	35.38	4,843	171,345		Aug 04 04:03 PM
ARSENIADIS JAMES	VP & Chief Accounting Officer	Jun 22 '25	Option Exercise	0.00	4,662	0	13,144	Jun 24 04:55 PM
ASHKEN IAN G H	Director	Jun 14 '25	Option Exercise	0.00	3,810	0	3,810	Jun 17 05:49 PM
ASHKEN IAN G H	Director	May 05 '25	Sale	42.72	150,000	6,408,000	5,612,102	May 07 05:58 PM
LILLIE JAMES E	Director	May 05 '25	Sale	42.73	200,000	8,546,000	5,088,734	May 07 05:58 PM
LILLIE JAMES E	Director	May 05 '25	Sale	42.73	50,000	2,136,500	996,203	May 07 05:58 PM
Lambert Louis	SVP, Gen Counsel & Secretary	May 02 '25	Sale	41.23	7,096	292,568	340	May 06 04:27 PM
Lambert Louis	Officer	May 02 '25	Proposed Sale	41.23	7,096	292,568		May 02 05:18 PM
JACKOLA GLENN DAVID	Interim CFO	Mar 09 '25	Option Exercise	0.00	5,217	0	11,025	Mar 11 04:19 PM
Becker Russell A.	President and CEO	Mar 09 '25	Option Exercise	0.00	160,951	0	1,558,414	Mar 11 04:19 PM
MORTON KRISTINA M	SVP and Chief People Officer	Mar 09 '25	Option Exercise	0.00	25,678	0	63,589	Mar 11 04:19 PM
LILLIE JAMES E	Director	Mar 03 '25	Sale	37.97	200,000	7,593,433	5,288,734	Mar 05 05:42 PM
LILLIE JAMES E	Director	Mar 03 '25	Sale	37.97	50,000	1,898,359	1,046,203	Mar 05 05:42 PM
ASHKEN IAN G H	Director	Mar 03 '25	Sale	37.84	200,000	7,568,795	5,762,102	Mar 05 05:42 PM
James E. Lillie	Director	Mar 03 '25	Proposed Sale	39.23	500,000	19,615,000		Mar 03 05:22 PM
Ian G. H. Ashken	Director	Mar 03 '25	Proposed Sale	39.23	350,000	13,730,500		Mar 03 05:20 PM
Becker Russell A.	President and CEO	Mar 01 '25	Option Exercise	0.00	22,297	0	1,408,434	Mar 03 05:04 PM
Becker Russell A.	President and CEO	Feb 27 '25	Option Exercise	0.00	32,451	0	1,402,103	Mar 03 05:04 PM
Lambert Louis	SVP, Gen Counsel & Secretary	Mar 01 '25	Option Exercise	0.00	3,586	0	9,201	Mar 03 05:04 PM
Lambert Louis	SVP, Gen Counsel & Secretary	Feb 27 '25	Option Exercise	0.00	4,982	0	8,174	Mar 03 05:04 PM
MORTON KRISTINA M	SVP and Chief People Officer	Mar 01 '25	Option Exercise	0.00	2,945	0	39,302	Mar 03 05:04 PM
MORTON KRISTINA M	SVP and Chief People Officer	Feb 27 '25	Option Exercise	0.00	4,057	0	38,383	Mar 03 05:04 PM
ARSENIADIS JAMES	VP & Chief Accounting Officer	Mar 01 '25	Option Exercise	0.00	559	0	8,767	Mar 03 05:03 PM
ARSENIADIS JAMES	VP & Chief Accounting Officer	Feb 27 '25	Option Exercise	0.00	854	0	8,643	Mar 03 05:03 PM
JACKOLA GLENN DAVID	Interim CFO	Mar 01 '25	Option Exercise	0.00	932	0	6,215	Mar 03 05:03 PM
JACKOLA GLENN DAVID	Interim CFO	Feb 27 '25	Option Exercise	0.00	1,423	0	5,904	Mar 03 05:03 PM
Becker Russell A.	President and CEO	Feb 24 '25	Option Exercise	0.00	207,994	0	1,471,980	Feb 26 04:35 PM
JACKOLA GLENN DAVID	Interim CFO	Feb 24 '25	Option Exercise	0.00	5,900	0	7,172	Feb 26 04:34 PM

Open in Screener

FDMT

4D Molecular Therapeutics Inc

Feb 13 • 04:00PM ET

9.35

-0.01 -0.11 %

Healthcare • Biotechnology • USA • NASD

FDMT 4D Molecular Therapeutics Inc daily Stock Chart

Peers: VRTX REGN BIIB SRPT CRSP NTLA EDIT BLUE ARWR SGMO

| Held by: XBI VTI IWM VXF IBB IWN KOMP SCHA VTWO VFMO

Index	RUT	P/E	-	EPS (ttm)	-3.94	Insider Own	10.05%	Shs Outstand	46.77M	Perf Week	4.00%
Market Cap	476.92M	Forward P/E	-	EPS next Y	-3.48	Insider Trans	-0.25%	Shs Float	45.88M	Perf Month	6.74%
Enterprise Value	194.12M	PEG	-	EPS next Q	-0.53	Inst Own	76.57%	Short Float	20.23%	Perf Quarter	-14.77%
Income	-209.18M	P/S	3974.33	EPS this Y	-9.35%	Inst Trans	-0.88%	Short Ratio	10.32	Perf Half Y	31.69%
Sales	0.12M	P/B	1.19	EPS next Y	-6.75%	ROA	-40.70%	Short Interest	9.28M	Perf YTD	24.67%
Book/sh	7.89	P/C	1.56	EPS next 5Y	-6.34%	ROE	-45.38%	52W High	12.34 -24.23%	Perf Year	98.09%
Cash/sh	5.98	P/FCF	-	EPS past 3/5Y	-5.06% -9.89%	ROIC	-54.25%	52W Low	2.23 318.34%	Perf 3Y	-52.83%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-87.29% -64.94%	Gross Margin	-6090.83%	Volatility	5.89% 7.27%	Perf 5Y	-79.18%
Dividend TTM	-	EV/Sales	1617.67	EPS Y/Y TTM	-43.93%	Oper. Margin	-191982.50%	ATR (14)	0.61	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.42	Sales Y/Y TTM	-	Profit Margin	-174314.17%	RSI (14)	58.02	Recom	1.45
Dividend Gr. 3/5Y	- -	Current Ratio	8.42	EPS Q/Q	-28.41%	SMA20	7.94%	Beta	2.98	Target Price	33.11
Payout	-	Debt/Eq	0.06	Sales Q/Q	2900.00%	SMA50	6.10%	Rel Volume	0.76	Prev Close	9.36
Employees	227	LT Debt/Eq	0.04	Earnings	Nov 10 BMO	SMA200	29.95%	Avg Volume	899.66K	Price	9.35
IPO	Dec 11, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-2.79% -68.74%	Trades		Volume	684,813	Change	-0.11%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-28-26	Resumed	Barclays	Overweight	$33
Nov-07-25	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jan-13-25	Downgrade	BMO Capital Markets	Outperform → Market Perform	$40 → $15
Nov-21-24	Initiated	Morgan Stanley	Underweight	$8
Sep-23-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Apr-15-24	Initiated	Barclays	Overweight	$459
Apr-15-24	Initiated	Barclays	Overweight	$45
Feb-07-24	Resumed	Goldman	Buy	$81
Oct-26-23	Initiated	RBC Capital Mkts	Outperform	$25
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$32
Oct-18-23	Upgrade	Leerink Partners	Market Perform → Outperform	$24
Jul-05-23	Initiated	Chardan Capital Markets	Buy	$30
Jan-30-23	Initiated	BMO Capital Markets	Outperform	$50
Nov-18-22	Initiated	H.C. Wainwright	Buy	$36
Nov-15-22	Upgrade	Goldman	Neutral → Buy	$12 → $68
Aug-12-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$12
Jun-22-22	Initiated	Jefferies	Buy	$22
Jan-04-22	Initiated	SVB Leerink	Outperform	$30
Jan-05-21	Initiated	Goldman	Neutral	$44
Jan-05-21	Initiated	Evercore ISI	Outperform	$70

Show Previous Ratings

Feb-13-26 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
Feb-09-26 08:00AM	4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD (GlobeNewswire)
Feb-02-26 09:53AM	Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT) (Insider Monkey)
Jan-17-26 08:00AM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
Jan-07-26 08:00AM	4DMT Provides Company Update and Anticipated Development Milestones for 2026 (GlobeNewswire) +8.07%
07:43AM	Loading…
Dec-27-25 07:43AM	Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely (Insider Monkey)
Dec-17-25 07:00AM	4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease (GlobeNewswire) -20.05%
Dec-12-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
Dec-08-25 08:00AM	4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-20-25 08:00AM	4DMT to Participate in 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-17-25 06:00AM	4DMT Appoints Kristian Humer as Chief Financial Officer (GlobeNewswire)
Nov-14-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
Nov-10-25 09:15AM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:00AM	4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire)
Nov-06-25 04:05PM	4DMT to Participate in Jefferies 2025 London Healthcare Conference (GlobeNewswire)
06:23AM	Loading…
06:23AM	4DMT Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
06:00AM	4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150's Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years (GlobeNewswire)
Oct-30-25 11:02PM	4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific (GlobeNewswire)
Oct-26-25 06:05AM	4D Molecular Therapeutics Secures Up to $11M More from CF Foundation to Accelerate 4D-710 Development (Insider Monkey)
Oct-17-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire) +14.53%
09:55AM	Wall Street Analysts See a 208.52% Upside in 4D Molecular Therapeutics (FDMT): Can the Stock Really Move This High? (Zacks)
Oct-14-25 08:00AM	4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference (GlobeNewswire)
Oct-13-25 08:00AM	4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation (GlobeNewswire) +8.65%
Sep-12-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
Sep-11-25 12:45PM	SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag (Zacks)
Sep-05-25 03:12AM	Jim Cramer on 4D Molecular Therapeutics: "This is a Pure Spec" (Insider Monkey) +9.98%
Sep-02-25 08:20PM	Lightning Round: Now is time to take a little off the table with Applovin, says Jim Cramer (CNBC TV) +5.37%
08:00AM	4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness (GlobeNewswire)
Aug-25-25 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-15-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
06:55PM	Loading…
Aug-11-25 06:55PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +11.21%
08:00AM	4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire)
Aug-06-25 08:00AM	4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference (GlobeNewswire) -5.29%
Jul-31-25 04:05PM	4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update (GlobeNewswire) +42.67%
Jul-28-25 07:21AM	AAV for the Hereditary Retinal Diseases Market Competitive Landscape Report 2025 \| Novartis, MeiraGTx, 4D Molecular Therapeutics, and Beacon Therapeutics Lead the Charge in Innovative Therapies (GlobeNewswire)
Jul-24-25 08:00AM	4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists (GlobeNewswire)
Jul-21-25 08:00AM	BBOT Appoints Industry Veteran Uneek Mehra as Chief Financial Officer (Business Wire)
Jul-11-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire)
Jul-02-25 04:05PM	4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution (GlobeNewswire)
May-28-25 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-16-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire) +7.50% +10.47%
May-08-25 05:50PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:05PM	4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire)
May-05-25 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.05%
May-02-25 06:51AM	FDA awards RMAT status to 4DMT diabetic macular oedema therapy (Pharmaceutical Technology) +9.30%
May-01-25 08:00AM	4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME (GlobeNewswire)
Apr-11-25 04:05PM	4DMT Announces New Employment Inducement Grants (GlobeNewswire) +5.70%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -7.43%
Mar-27-25 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-10-25 08:00AM	4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD (GlobeNewswire)
Mar-04-25 08:05AM	4D Molecular price target lowered to $35 from $39 at RBC Capital (TipRanks)
Feb-28-25 04:05PM	4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire) -8.61%
Feb-19-25 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-08-25 02:30PM	4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program (GlobeNewswire)
Jan-29-25 08:00AM	4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population (GlobeNewswire) +7.53%
Jan-10-25 08:00AM	4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD and DME and 4D-710 in CF and Extends Cash Runway (GlobeNewswire) -5.48%
08:00AM	4DMT Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway (GlobeNewswire)
08:00AM	4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path (GlobeNewswire)
Dec-16-24 08:00AM	4DMT Announces Landmark Publication of 4D-150 Preclinical Data for the Treatment of Neovascular Retinopathies in IOVS (GlobeNewswire)
Nov-26-24 06:51AM	4D Molecular Therapeutics, Inc. (FDMT): An Oversold Healthcare Stock to Invest In Now (Insider Monkey)
Nov-14-24 08:00AM	4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV (GlobeNewswire)
Nov-13-24 05:20PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones (GlobeNewswire)
Sep-25-24 09:35AM	4D Molecular Therapeutics (FDMT) Loses -26.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Sep-23-24 08:00AM	4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference (GlobeNewswire)
Sep-19-24 02:34PM	4D Molecular Therapeutics Stock Falls After Follow-Up Data From Mid-Stage Study Of Vision Loss Drug Candidate (Benzinga) -19.74%
10:30AM	4D Molecular data bode well for eye gene therapy, but shares fall (BioPharma Dive)
Sep-18-24 04:05PM	4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day (GlobeNewswire)
Sep-05-24 08:00AM	4DMT Announces Presentations at Upcoming Retina Conferences (GlobeNewswire)
Sep-03-24 08:00AM	4DMT to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-27-24 08:00AM	4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024 (GlobeNewswire)
Aug-23-24 09:35AM	4D Molecular Therapeutics (FDMT) Loses -21.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Aug-12-24 08:00AM	4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-08-24 05:55PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire)
Aug-05-24 08:00AM	4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board (GlobeNewswire) -5.97%
Jul-17-24 05:00AM	4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity (GlobeNewswire) -31.96%
Jul-12-24 09:40AM	4D Molecular Therapeutics (FDMT) Moves 11.1% Higher: Will This Strength Last? (Zacks) +5.54%
Jul-08-24 05:52PM	4D Molecular Therapeutics, Inc. (FDMT): Why Are Analysts Bullish On This Shorted Stock? (Insider Monkey) +5.58%
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
Jun-24-24 08:00AM	4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy (GlobeNewswire)
Jun-18-24 08:00AM	4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast (GlobeNewswire)
Jun-08-24 04:30PM	4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting (GlobeNewswire)
Jun-06-24 07:30AM	4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference (GlobeNewswire) -17.27%
Jun-04-24 08:00AM	4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting (GlobeNewswire)
Jun-03-24 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-30-24 08:00AM	4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47 European Cystic Fibrosis Conference (GlobeNewswire)
May-10-24 01:48PM	4D Molecular Therapeutics Inc (FDMT) Q1 2024 Earnings: Misses Analyst Net Income Projections (GuruFocus.com)
May-09-24 11:55PM	FDMT Stock Earnings: 4D Molecular Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:05PM	4DMT Reports First Quarter 2024 Financial Results and Operational Highlights (GlobeNewswire)
May-07-24 08:00AM	4DMT to Participate in Upcoming Investor Conference (GlobeNewswire)
May-01-24 10:01AM	4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks) +6.10%
08:00AM	4DMT Announces Presentations at ARVO 2024 Annual Meeting (GlobeNewswire)
Apr-04-24 01:30AM	4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 Shares (GuruFocus.com)
Mar-29-24 07:01PM	4D Molecular Therapeutics Inc's Chief Legal Officer Sells Company Shares (GuruFocus.com)
Mar-28-24 08:00AM	4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis (GlobeNewswire) -11.18%
Mar-04-24 08:00AM	4DMT to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-02-24 04:32AM	4D Molecular Therapeutics Inc Reports Full Year 2023 Financial Results (GuruFocus.com)
Feb-29-24 06:05PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	4DMT Reports Full Year 2023 Financial Results and Operational Highlights (GlobeNewswire)

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gupta Ashoo	VP, Finance and Controller	Dec 20 '25	Sale	8.68	389	3,377	46,218	Dec 23 09:05 PM
Bizily Scott	Chief Legal Officer	Dec 16 '25	Option Exercise	4.14	1,635	6,769	5,229	Dec 19 04:10 PM
Bizily Scott	Chief Legal Officer	Dec 16 '25	Sale	10.90	1,635	17,822	3,594	Dec 19 04:10 PM
THEUER CHARLES	Director	Dec 12 '25	Option Exercise	1.14	9,333	10,640	41,684	Dec 16 04:35 PM
SCOTT BIZILY	Officer	Dec 16 '25	Proposed Sale	10.95	1,635	17,903		Dec 16 04:33 PM
Bizily Scott	Chief Legal Officer	Nov 17 '25	Option Exercise	4.14	1,635	6,769	5,229	Nov 19 09:53 PM
Bizily Scott	Chief Legal Officer	Nov 17 '25	Sale	10.59	1,635	17,315	3,594	Nov 19 09:53 PM
SCOTT BIZILY	Officer	Nov 17 '25	Proposed Sale	10.79	1,635	17,642		Nov 17 04:33 PM
Bizily Scott	Chief Legal Officer	Oct 24 '25	Option Exercise	6.49	1,084	7,035	6,272	Oct 27 06:19 PM
Bizily Scott	Chief Legal Officer	Oct 24 '25	Sale	12.00	2,678	32,136	3,594	Oct 27 06:19 PM
SCOTT BIZILY	Officer	Oct 24 '25	Proposed Sale	10.00	1,816	18,160		Oct 24 04:26 PM
Bizily Scott	Chief Legal Officer	Oct 16 '25	Option Exercise	4.14	1,635	6,769	6,823	Oct 20 07:51 PM
Bizily Scott	Chief Legal Officer	Oct 16 '25	Sale	10.17	1,635	16,628	5,188	Oct 20 07:51 PM
Bizily Scott	Chief Legal Officer	Oct 09 '25	Sale	10.00	2,408	24,080	5,188	Oct 14 04:04 PM
Bizily Scott	Chief Legal Officer	Sep 23 '25	Sale	8.00	2,407	19,256	7,596	Sep 26 09:50 PM
SCOTT BIZILY	Officer	Sep 23 '25	Proposed Sale	7.40	7,312	54,109		Sep 23 04:20 PM

BBIO

BridgeBio Pharma Inc

APG

APi Group Corporation

FDMT

4D Molecular Therapeutics Inc

Upgrade your FINVIZ experience